By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ocular Therapeutix, Inc. 

204 Second Avenue

Waltham  Massachusetts  02451  U.S.A.
Phone: 781-895-3235 Fax: 781-895-3236


SEARCH JOBS


Industry
Biotechnology






Company News
Ocular Therapeutix (OCUL) To Present Additional Phase III Data And Patient Reported Outcomes Results For DEXTENZA At American Society of Cataract & Refractive Surgery Symposium 4/24/2017 7:58:20 AM
Ocular Therapeutix (OCUL) Appoints George Migausky As Interim Chief Financial Officer 4/6/2017 8:21:09 AM
New Publication Describes Positive Patient Experience In Study Of Ocular Therapeutix (OCUL)’s DEXTENZA Following Cataract Surgery 3/15/2017 6:48:52 AM
Ocular Therapeutix (OCUL) Reports Fourth Quarter And Full Year 2016 Financial Results 3/10/2017 6:29:23 AM
Ocular Therapeutix (OCUL) To Report Fourth Quarter And Full Year 2016 Financial Results 3/8/2017 8:03:12 AM
Ocular Therapeutix (OCUL) Announces FDA Acceptance Of NDA Resubmission For DEXTENZA For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery 2/22/2017 6:23:25 AM
Ocular Therapeutix (OCUL) Eyes $25 Million in Public Offering 1/24/2017 6:46:39 AM
Ocular Therapeutix (OCUL) Release: Biopharma Resubmits NDA For DEXTENZA For The Treatment Of Ocular Pain Occurring After Ophthalmic Surgery 1/23/2017 7:47:39 AM
Ocular Therapeutix (OCUL) Jumps on More Positive Study Data for Dextenza 1/4/2017 6:45:19 AM
Ocular Therapeutix (OCUL) Announces Successful Topline Results For Both Inflammation And Pain Primary Efficacy Endpoints From Phase 3 Clinical Trial Of DEXTENZA 11/14/2016 11:39:22 AM
12345678910...
//-->